DK3198009T3 - Onkolytiske tumorvira og anvendelsesfremgangsmåder - Google Patents
Onkolytiske tumorvira og anvendelsesfremgangsmåder Download PDFInfo
- Publication number
- DK3198009T3 DK3198009T3 DK15843893.7T DK15843893T DK3198009T3 DK 3198009 T3 DK3198009 T3 DK 3198009T3 DK 15843893 T DK15843893 T DK 15843893T DK 3198009 T3 DK3198009 T3 DK 3198009T3
- Authority
- DK
- Denmark
- Prior art keywords
- methods
- tumor viruses
- oncolytic
- oncolytic tumor
- viruses
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
- C12N2810/6009—Vectors comprising as targeting moiety peptide derived from defined protein from viruses dsDNA viruses
- C12N2810/6018—Adenoviridae
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
- C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
- C12N2810/855—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from receptors; from cell surface antigens; from cell surface determinants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462054724P | 2014-09-24 | 2014-09-24 | |
| PCT/US2015/051745 WO2016049201A1 (en) | 2014-09-24 | 2015-09-23 | Oncolytic tumor viruses and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3198009T3 true DK3198009T3 (da) | 2021-11-22 |
Family
ID=55581955
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK15843893.7T DK3198009T3 (da) | 2014-09-24 | 2015-09-23 | Onkolytiske tumorvira og anvendelsesfremgangsmåder |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20170202893A1 (enExample) |
| EP (2) | EP4043021A3 (enExample) |
| JP (3) | JP6764859B2 (enExample) |
| KR (3) | KR20250081944A (enExample) |
| CN (1) | CN108064275A (enExample) |
| AU (3) | AU2015320665B2 (enExample) |
| CA (1) | CA2961748A1 (enExample) |
| DK (1) | DK3198009T3 (enExample) |
| ES (1) | ES2899913T3 (enExample) |
| PL (1) | PL3198009T3 (enExample) |
| WO (1) | WO2016049201A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2903582C (en) | 2013-03-14 | 2021-06-08 | Salk Institute For Biological Studies | Oncolytic adenovirus compositions |
| DK3198009T3 (da) * | 2014-09-24 | 2021-11-22 | Salk Inst For Biological Studi | Onkolytiske tumorvira og anvendelsesfremgangsmåder |
| ES2837400T3 (es) * | 2015-10-05 | 2021-06-30 | Salk Inst For Biological Studi | Adenovirus sintético con tropismo para los tejidos dañados para su uso en la promoción de la reparación de heridas y regeneración tisular |
| JP7015551B2 (ja) | 2016-02-23 | 2022-02-15 | ソーク インスティテュート フォー バイオロジカル スタディーズ | ウイルス動態への影響を最小限にするための治療用アデノウイルスにおける外因性遺伝子発現 |
| WO2017147265A1 (en) | 2016-02-23 | 2017-08-31 | Salk Institute For Biological Studies | High throughput assay for measuring adenovirus replication kinetics |
| CA3045892A1 (en) * | 2016-12-12 | 2018-06-21 | Salk Institute For Biological Studies | Tumor-targeting synthetic adenoviruses and uses thereof |
| WO2018125970A1 (en) * | 2016-12-30 | 2018-07-05 | Salk Institute For Biological Studies | Synthetic adenoviruses targeting bone tissue and uses thereof |
| SG11201906973TA (en) * | 2017-01-30 | 2019-08-27 | Epicentrx Inc | Multiple transgene recombinant adenovirus |
| EA201990822A1 (ru) | 2017-04-12 | 2020-01-09 | Эписентарикс, Инк. | Иммуномодулирующие слитые белки |
| EP3773649A4 (en) | 2018-03-28 | 2022-02-23 | EpicentRx, Inc. | PERSONALIZED CANCER VACCINE |
| BR112020019942A2 (pt) * | 2018-04-09 | 2021-01-26 | Salk Institute For Biological Studies | composições de adenovírus oncolítico com propriedades de replicação aprimoradas |
| CN111363726A (zh) * | 2018-12-26 | 2020-07-03 | 上海元宋生物技术有限公司 | 表达干扰素的溶瘤病毒及其应用 |
| WO2020172509A1 (en) * | 2019-02-21 | 2020-08-27 | Unleash Immuno Oncolytics, Inc. | Oncolytic adenoviral vector and methods of use |
| US20220354911A1 (en) * | 2019-09-05 | 2022-11-10 | Klinikum Rechts Der Isar Der Technischen Universität München | Treatment of tumors by a combination of an oncolytic adenovirus, a cdk4/6 inhibitor and a further therapeutically active agent |
| EP3812465A1 (en) * | 2019-10-21 | 2021-04-28 | Universität Ulm | Adenovirus comprising a modified adenovirus hexon protein |
| JP2023513794A (ja) * | 2020-02-14 | 2023-04-03 | ソーク インスティテュート フォー バイオロジカル スタディーズ | Ｕｌｋ１／２の阻害剤およびその使用方法 |
| AU2021306714A1 (en) * | 2020-07-06 | 2023-02-02 | Salk Institute For Biological Studies | Oncolytic adenovirus with replication selectivity based on status of p53 transcriptional activity |
| WO2022236080A2 (en) * | 2021-05-06 | 2022-11-10 | Asimov Inc. | Compositions and methods for adeno-associated viral production |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030138405A1 (en) * | 2001-04-17 | 2003-07-24 | Juan Fueyo | Conditionally replicative adenovirus to target the Rb and Rb-related pathways |
| ATE546531T1 (de) * | 2003-12-31 | 2012-03-15 | Kalobios Inc | Transaktivierungssystem für säugerzellen |
| US7473418B2 (en) * | 2004-03-25 | 2009-01-06 | Cell Genesys, Inc. | Pan cancer oncolytic vectors and methods of use thereof |
| EP2606127B1 (en) * | 2010-08-16 | 2019-03-20 | Salk Institute For Biological Studies | Adenoviral assembly method |
| CA2867129C (en) * | 2012-03-13 | 2023-11-21 | Salk Institute For Biological Studies | Selective cell targeting using adenovirus and chemical dimers |
| CA2903582C (en) * | 2013-03-14 | 2021-06-08 | Salk Institute For Biological Studies | Oncolytic adenovirus compositions |
| WO2014170389A1 (en) * | 2013-04-18 | 2014-10-23 | Tilt Biotherapeutics Oy | Enhanced adoptive cell therapy |
| DK3198009T3 (da) | 2014-09-24 | 2021-11-22 | Salk Inst For Biological Studi | Onkolytiske tumorvira og anvendelsesfremgangsmåder |
-
2015
- 2015-09-23 DK DK15843893.7T patent/DK3198009T3/da active
- 2015-09-23 WO PCT/US2015/051745 patent/WO2016049201A1/en not_active Ceased
- 2015-09-23 EP EP21193392.4A patent/EP4043021A3/en active Pending
- 2015-09-23 PL PL15843893T patent/PL3198009T3/pl unknown
- 2015-09-23 AU AU2015320665A patent/AU2015320665B2/en active Active
- 2015-09-23 KR KR1020257017356A patent/KR20250081944A/ko active Pending
- 2015-09-23 CA CA2961748A patent/CA2961748A1/en active Pending
- 2015-09-23 KR KR1020177011121A patent/KR102608590B1/ko active Active
- 2015-09-23 KR KR1020237040919A patent/KR102814615B1/ko active Active
- 2015-09-23 EP EP15843893.7A patent/EP3198009B1/en active Active
- 2015-09-23 ES ES15843893T patent/ES2899913T3/es active Active
- 2015-09-23 JP JP2017515974A patent/JP6764859B2/ja active Active
- 2015-09-23 CN CN201580063723.9A patent/CN108064275A/zh active Pending
-
2017
- 2017-03-24 US US15/468,565 patent/US20170202893A1/en active Pending
-
2020
- 2020-09-14 JP JP2020153724A patent/JP7416423B2/ja active Active
-
2022
- 2022-05-24 AU AU2022203504A patent/AU2022203504B2/en active Active
-
2023
- 2023-12-22 JP JP2023216375A patent/JP2024038030A/ja active Pending
-
2025
- 2025-05-13 AU AU2025203440A patent/AU2025203440A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022203504B2 (en) | 2025-02-20 |
| JP2017534263A (ja) | 2017-11-24 |
| EP4043021A3 (en) | 2022-11-23 |
| AU2015320665B2 (en) | 2022-06-16 |
| KR20230165385A (ko) | 2023-12-05 |
| EP3198009A1 (en) | 2017-08-02 |
| AU2022203504A1 (en) | 2022-06-09 |
| JP7416423B2 (ja) | 2024-01-17 |
| EP3198009A4 (en) | 2018-09-05 |
| JP2024038030A (ja) | 2024-03-19 |
| JP6764859B2 (ja) | 2020-10-07 |
| KR102608590B1 (ko) | 2023-12-01 |
| EP4043021A2 (en) | 2022-08-17 |
| KR20250081944A (ko) | 2025-06-05 |
| AU2015320665A1 (en) | 2017-04-06 |
| EP3198009B1 (en) | 2021-09-08 |
| JP2021007392A (ja) | 2021-01-28 |
| ES2899913T3 (es) | 2022-03-15 |
| WO2016049201A1 (en) | 2016-03-31 |
| KR20170063801A (ko) | 2017-06-08 |
| KR102814615B1 (ko) | 2025-05-28 |
| PL3198009T3 (pl) | 2022-01-24 |
| AU2025203440A1 (en) | 2025-06-05 |
| CN108064275A (zh) | 2018-05-22 |
| US20170202893A1 (en) | 2017-07-20 |
| CA2961748A1 (en) | 2016-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3198009T3 (da) | Onkolytiske tumorvira og anvendelsesfremgangsmåder | |
| FIC20230014I1 (fi) | Foslevodopa ja foskarbidopa | |
| IL251970B (en) | Anti-cd79b antibodies and methods of use | |
| DK3653221T3 (da) | Anti-pvrig-antistoffer og anvendelsesfremgangsmåder | |
| DK3215532T3 (da) | Anti-TIM3-antistoffer og fremgangsmåder til anvendelse | |
| PL3353210T3 (pl) | Przeciwciała anty-TIGIT i sposoby stosowania | |
| HUE046000T2 (hu) | Antiproferatív vegyületek és alkalmazásuk módszerei | |
| HUE046756T2 (hu) | Benzoxazepin-oxazolidinon vegyületek és azok alkalmazási módszerei | |
| DK3215147T3 (da) | Neurodæmpende norketamin-forbindelser og fremgangsmåder | |
| PL3319808T3 (pl) | Sposoby wytwarzania dokumentów zabezpieczonych i urządzenia zabezpieczające | |
| IL249639A0 (en) | Endophytes, associated compositions, and methods of use thereof | |
| DK3221357T3 (da) | Fælles letkæder og fremgangsmåder til anvendelse | |
| DK3234133T3 (da) | Crispr-baserede sammensætninger og fremgangsmåder til anvendelse | |
| DK3205650T3 (da) | Egfr-hæmmer og fremstilling og anvendelse deraf | |
| DK3210977T3 (da) | Hidtil ukendt aminoalkylbenzothiazepinderivat og anvendelse deraf | |
| DK3235830T3 (da) | Interleukin-15-proteinkompleks og anvendelse deraf | |
| HUE052373T2 (hu) | Szubsztituált krománok és alkalmazási eljárások | |
| DK3218358T3 (da) | Ifluorometyl-aminopyridiner og difluorometyl-aminopyrimidiner | |
| BR112016016289A2 (pt) | heteroaris e usos dos mesmos | |
| DK3089971T3 (da) | Forbindelser og fremgangsmåder til anvendelse | |
| DK3218005T3 (da) | Glycan-interagerende forbindelser og anvendelsesfremgangsmåder | |
| PT3319612T (pt) | Oxisteróis e métodos de utilização dos mesmos | |
| LT3341027T (lt) | Transfekcijos kompleksai ir jų panaudojimo būdai | |
| EP3152293C0 (en) | PERFUSION CULTURE METHODS AND USES THEREOF | |
| DK3161139T3 (da) | Tlr-4-specifikke aptamerer og anvendelser heraf |